20.96
+4.85%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bausch + Lomb
From its filings with the US Securities and Exchange Commission
Bausch + Lomb is based in Vaughan, Ontario, Canada. Its shares trade on NYSE under the ticker BLCO. The SEC classifies its business as ophthalmic goods. In the fiscal year to 31 December 2025, it reported revenue of $5.10bn and a net loss of $360.0m. At that date it held total assets of $14.02bn and shareholders' equity of $6.45bn.
Bausch + Lomb Corporation (and its subsidiaries) (“Bausch + Lomb,” “we,” “us,” “our” or the “Company”) is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Founded in 1853, Bausch + Lomb has a significant global research, development, manufacturing and commercial footprint of approximately 13,000 employees and a presence in approximately 100 countries. As a fully integrated eye health business, Bausch + Lomb has a comprehensive portfolio of approximately 400 products, which includes an established line of contact lenses, intraocular lenses ("IOLs") and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market.
Bausch + Lomb is a subsidiary of Bausch Health Companies Inc. (“BHC”), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88% of the issued and outstanding common shares of Bausch + Lomb, as of February 11, 2026. On August 6, 2020, BHC announced its plan to separate our eye health business into an independent publicly traded entity, separate from the remainder of BHC (the “Separation”).
Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 6 May 2022
- Employees
- 13,000
- Website
- ir.bausch.com ↗
- Head office
- 520 APPLEWOOD CRESCENT, VAUGHAN, A6, L4K 4B4
- Classification
- Ophthalmic Goods
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Brenton SaundersChairman of the Board, Chief Executive Officer, since 2023$23.9m
- Mr. Sam EldessoukyChief Financial Officer, Executive Vice President$6.8m
- Mr. Luc BonnefoyPresident - Surgical
- Mr. Andrew StewartPresident - Global Pharmaceuticals and International Consumer$4.1m
- Mr. A. Robert BaileyExecutive Vice President, Chief Legal Officer$5.5m
- Dr. Yehia HashadExecutive Vice President - Research & Development, Chief Medical Officer$4.5m
- Mr. Thomas RossLead Independent Director$384,986
- Dr. Eduardo AlfonsoIndependent Director
- Mrs. Nathalie BernierIndependent Director$339,986
- Mr. Steven CollisIndependent Director
- Ms. Sarah KavanaghIndependent Director$352,486
- Ms. Karen LingIndependent Director$361,306
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bausch + Lomb Corp employs 12,900 full-time employees in Vaughan, Ontario.
- The Vision Care segment includes contact lens and consumer eye care products like Biotrue and Alaway.
- The Ophthalmic Pharmaceuticals segment offers generic treatments for glaucoma and dry eyes under brands like XIIDRA and Vyzulta.
Weaknesses
- The company has no presence in the Financials sector or Real Estate industry.
- Bausch + Lomb Corp's IPO occurred on 6 May 2022, limiting recent market data.
- The Surgical segment relies on cataract surgery equipment without diversification.
Opportunities
- The Vision Care segment can expand into emerging markets like India and Brazil.
- The Ophthalmic Pharmaceuticals segment can leverage generic drug demand in the U.S. market.
- The Surgical segment can introduce new technologies for retinal disease treatments.
Threats
- The Vision Care segment faces competition from Johnson & Johnson's contact lens business.
- The Ophthalmic Pharmaceuticals segment is vulnerable to regulatory changes in the U.S. healthcare system.
- The Surgical segment depends on cataract surgery equipment which may face technological disruption.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.